OpenForum – a blog by the Health and Human Rights community

a blog by the Health and Human Rights community

Posts Tagged ‘tuberculosis’

A Response to Amon et al.

[Editor's note: The following is a Letter to the Editors of Health and Human Rights: An International Journal from Andrea Boggio, Matteo Zignol, Ernesto Jaramillo, and Mario Raviglione in response to a recent Perspectives article written by Joseph J. Amon, François Girard, and Salmaan Keshavjee. This Perspectives article was itself a response to an earlier Health and Human Rights in Practice article by the authors of this letter. We encourage readers of OpenForum to weigh in on this issue through comments on this post.]

Dear Editors:

We read with interest the paper “Limitations on human rights in the context of drug-resistant tuberculosis: A reply to Boggio et al.” co-authored by Drs. Amon, Girard, and Keshavjee. While we welcome the effort to expand our framework[1] and we applaud the Authors for continuing the discussion on this extremely important topic, we believe that the paper by Amon and colleagues may be misleading to your Journal’s readership.

First, Amon and colleagues do not technically “reply” to our argument. They do not challenge any of our assumptions. To the contrary, they explicitly agree with all of them. In the abstract, they state “there is little international disagreement with [our] position.” A similar claim is made on page 2 (“Boggio et al., like others previously, argue that involuntary detention may legitimately be used in a limited number of cases. . . .  In theory, few would disagree”), page 6 (“Boggio et al. fairly describe the relationship of rights and health in theory”), and eventually offer conclusions that mirror precisely our own conclusions: “Only in exceptional cases, where patients resist treatment after all feasible programmatic solutions have been exhausted, should detention — with proper checks, balances, and safeguards — be considered” (p. 6, citations refer to the pdf version of the article). These considerations undermine the idea that Amon and colleagues’ paper is in reply to ours. If anything, it expands our arguments.

Second, Amon and colleagues criticize our paper as it is allegedly not “informed by practice” (p. 6). The claim is without merit, as our paper was intended to articulate the foundations of WHO’s recommendations for practice in the area of drug-resistant TB, drawing on the field experience of the co-authors and many others,[2] rather than providing a tool to be directly translated into practice. WHO’s involvement with control of drug-resistant TB is much broader than our paper, as Amon et al., know well; thus, characterizing it as not “informed by practice” does a disservice to the readership.

Third, Amon and colleagues claim that policies adopted by the South African government are in violations of international human rights law and that this may be caused by a “a narrow reading of [our] argument, coupled with [our] lack of explicit reference of what constitutes a ‘last resort’” (p. 6). After this statement, Amon and colleagues fail to provide any evidence — empirical or logical — of why our paper, if narrowly read, would be the cause of certain practices. We certainly did and do not endorse a lighthearted approach to coercive measures.

Finally, Amon and colleagues claim, in the abstract, that our paper raises a “false” dilemma. The authors’ explanation of why it is a false dilemma is that there is no need to breach individual rights for the sake of containing TB because, “given the early indications of success of Lesotho’s community-based treatment program, and the documented evidence of successful community-based models in other urban and rural settings, any assumption that isolation and other compulsory measures are necessary and effective for the treatment of drug-resistant TB must be reconsidered.” (p. 6). In other words, “early indications” suggest that there is not (nor will be) need for coercive measures. A few comments are needed on this characterization of our paper as presenting a “false” dilemma. First, without need to delve a complex philosophical debate on dilemmas,[3] it suffices to say that a dilemma is “true” if it can genuinely arise from practice (in our case, the tension between individual rights and public health considerations). A “true” dilemma can then be resolved and that does not turn it into a “false” dilemma: it simply becomes a “resolved” dilemma. Second, Amon and colleagues’ language itself suggests that evidence that coercive measures are never warranted is not robust enough. Therefore, they implicitly concede that the dilemma raised in our paper may in fact arise. As a matter of fact, sound and resourceful TB control programs sometimes deal with TB patients in which all measures have failed to promote adherence to treatment.[4] Furthermore, they also concede that it is unlikely to be resolved unless one resorts to coercive measures — once again under exceptional circumstances. Finally, Amon and colleagues advocate a course of action that is precisely what WHO has recommended for a long time: community-based measures and the DOTS strategy.


References

1. A. Boggio, M. Zignol, E. Jaramillo, et al. “Limitations on human rights: are they justifiable to reduce the burden of tuberculosis in the era of MDR- and XDR-TB?” Health and Human Rights: An International Journal 10/2 (2008), pp. 121-126. Available at http://www.hhrjournal.org/index.php/hhr/article/view/85/169 (html) and at http://www.hhrjournal.org/index.php/hhr/article/view/85/158 (pdf).

2. B. H. Lerner, “Catching Patients: Tuberculosis and Detention in 1990s,” Chest 1115/1 (1999), pp. 236-241; “How Israel Manages Noncompliant TB Patients” Biot Report #437 (July 05, 2007). Available at http://www.semp.us/publications/biot_printview.php?BiotID=437.

3. T. McConnell, “Moral Dilemmas,” The Stanford Encyclopedia of Philosophy (Winter 2003 Edition), E. N. Zalta (ed). Available at http://plato.stanford.edu/entries/moral-dilemmas/.

4. See note 2.

Fighting TB from every angle: New breakthroughs in detection and treatment

Two new studies suggest promising methods of detecting and treating TB despite discouraging reports about the increasing global prevalence of multi-drug resistant tuberculosis (MDR-TB) and extensively-drug-resistant tuberculosis (XDR-TB). The first study underlines the importance of follow-up visits in detecting TB among immigrants and asylum seekers entering the US. While screening is crucial in preventing the spread of TB, identifying TB-infected persons can be difficult; blood or sputum smear testing can take weeks to complete and has only a 50% accuracy rate. Screening of immigrants and asylum seekers is especially important, as the TB rate in foreign-born persons is 9.7 times higher than in US-born persons. Researchers found that follow-up visits with immigrants after their entry into the US were effective in identifying and reducing the number of TB patients in the US.

The World Health Organization estimated 9.27 million cases of TB in 2007, a significant increase from 6.6 million cases in 1990. The majority of these cases are found in the South-East Asia region, which accounts for 34% of all new cases, and sub-Saharan Africa, which has the highest TB mortality rate in the world. People with health conditions that weaken the immune system like HIV infection, substance abuse, or malnutrition are more susceptible to the disease. A recent study showed that one-fourth of all TB-related deaths were in patients who were also HIV-positive.

No new classes of TB drugs have been created since the 1960s, and few clinical trials have been conducted using modern regulatory standards. To address this need, research groups are focusing on novel approaches to TB therapeutics. The Global Alliance for TB Drug Development (TB Alliance) recently announced four research partnerships that will explore new methods of treating drug-resistant TB. One of these collaborations, led by Anacor Pharmaceuticals, will provide any new compounds developed to the TB Alliance royalty-free. Read more